Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
H009 vs esomeprazole in peptic ulcer bleeding
CTR20233570Phase 3Completed
- Sponsor
- Nanjing Kefeiping Pharmaceutical
- Start
- Nov 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of vonoprazan in Peptic ulcer disease (PUD) and upper gastrointestinal bleeding (UGIB) (2 arms), sponsored by Nanjing Kefeiping Pharmaceutical. Primary endpoint: Proportion of subjects without rebleeding within 72 hours after start of administration (endoscopic assessment). Started Nov 2023; status: completed.
02
Drugs
vonoprazan
03
Conditions
Peptic ulcer disease (PUD)upper gastrointestinal bleeding (UGIB)
Beyond the preview
Go deeper on CTR20233570.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20233570.